Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

The rise of China, the buzz around AI, challenging global market dynamics, the recent surge in dealmaking and exciting new ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

A longitudinal study suggests the developmental window for complex language comprehension closes much earlier in autistic ...

AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

For almost ten years, red MAGA hats have been an immediately identifiable sign of one’s political affiliation with president ...

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...

Anthropic launched Cowork, bringing the autonomous capabilities of its developer-focused Claude Code tool to non-technical ...

Amber Implants, a Netherlands medtech developing next-generation implants for spinal injuries, named Vincent Gardès as CEO.

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

Information pervades the universe, yet means nothing. Meaning emerged when matter organized into systems that could ...